Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE +0.05%, DAX +0.11%, CAC40 +0.26%

Dec 11 ,2023

  • Synopsis

    • European equity markets set to open marginally higher extending last week's gains (Stoxx Europe 600 closed up 1.3%). European equity indexes surged in the first week of December with the Stoxx 600 index hitting its highest level since early 2022, rising over 10% since late October amid ramping up expectations of central bank rate cuts next year. Those expectations may change this week with decisions due from the BoE, ECB, Norges Bank, and SNB.

    • Also on this week's agenda are IEA, OPEC oil market reports, Eurozone, France, Germany, UK Dec flash manufacturing/services PMIs, Germany Dec ZEW economic sentiment, UK Nov claimant count as well as earnings/updates from the likes of Bunzl (BNZL.LN), H&M Hennes & Mauritz (HM.B.SS), Inditex (ITX.SM) and VINCI (DG.FP).

    • Today's data releases include Norway Nov CPI, PPI, Denmark Nov CPI, Oct trade balance,

    • In the UK, property portal Rightmove has reported that the average new seller asking price fell by 1.9% month-on-month. While prices usually fall in December because of seasonal factors, this month's drop is bigger than the average decrease of 1.5% over the past 20 years, according to Rightmove. (Guardian)

    • Focus on UK politics. Reuters notes UK PM Sunak faces the most dangerous moment of his premiership this week, when he is due to appear before a COVID-19 inquiry and must win a crunch vote in parliament on his plan to revive a policy to send asylum seekers to Rwanda.

    • Asian equities trading mixed Monday. India's Sensex at record high. China consumer and producer price deflation intensified in November.

    • Today's aganda also sees German coalition leaders to resume budget talks. Also EU foreign ministers meeting. Presidents of Latvia, Rinkevics, and Lithuania, Nauseda, will visit Estonia at the invitation of Estonian President Karis, joint press conf at 10:15 CET. In UK, parliamentary committee topics include Scotland (15:00GMT). EU's von der Leyen meets with EP President Metsola. EU's Šef�?ovi�? participates in an event organised by BritCham, the British Chamber of Commerce EU & Belgium. In the Netherlands, following meetings with leaders of parties which may go on to form a right-wing coalition, scout Ronald Plasterk is due to hand over his report on forming a new government to parliament. In the morning, Chancellor Scholz hosts Dutch PM Rutte.

    • In central banks, Riksbank's Bunge speech at 13:00CET at a seminar organised by the Swedish Association of Corporate Treasurers. Bank of Italy's Perrazzelli speech at 10:00CET and 16:15 at the conf 'New Frontiers in Banking and Capital Markets'. ECB's McCaul panellist at 21:10CET at event organised by Capital Link, others speakers include PM Mitsotakis 14:00.

    • Also of note, first day of trading for Syensqo (SYENS.BB) spin-off from Solvay (SOLB.BB)

  • Macro/politics

    • UK

      • PM Sunak battles to unite divided party in pivotal week - Reuters

      • Can Rishi Sunak avoid becoming a victim of the Tory civil war? - FT

      • UK Economists Say Bank of England May Warn Against Rate Cut Bets - Bloomberg

      • Average asking price for a UK home has dropped by almost £7,000 this month - Guardian, citing Rightmove

      • UK Finance predicts lending for house purchases will fall by 8% over 2024 - Bloomberg

      • Talk of Johnson-Farage plot and a snap election may be wide of the mark - but PM is still facing a crisis sooner or later - Sky News

    • Ireland

      • Northern Ireland political parties to hold budget crisis talks - RTE

    • Semiconductors

      • South Korean President Yoon to visit Netherlands to boost chip cooperation - Taipei Times

    • Germany

      • Coalition to Reconvene Talks on 2024 Budget on Monday - Bloomberg

  • Top company news

    • Earnings/updates

      • INVE.B.SS (Investor) -- releases presentation material in connection with its CMD

    • M&A

      • FME.GR (Fresenius Medical Care) -- Binding offers for Cura Day Hospitals due on 12-Dec; all three suitors still in the race - Australian Financial Review

      • VIV.FP (Vivendi) -- Suitors enter race for Vivendi's See Tickets - FT

      • SGO.FP (Compagnie de Saint-Gobain) -- Saint-Gobain seeking more acquisitions outside Europe - FT

      • EVK.GR (Evonik Industries) -- Evonik CFO discusses asset sales, business transformation and dividends in an interview with Börsen-Zeitung

      • BG.AV (BAWAG Group) -- signs sale and purchase agreement with Dexia concerning last remaining leasing activities of the Dexia Group

      • RE.FP (Colas) -- Bouygues to proceed with the squeeze out of the remaining Colas shares at €175/share

      • Endeavor Energy (private) reportedly considering sale at potential valuation of $25-30B -- Reuters

    • Healthcare

      • ABBV (AbbVie) -- announces new data for Bispecific antibody Epcoritamab shows strong, durable treatment response for patients with difficult-to-treat R/R FL

      • AZN.LN (AstraZeneca) -- presents results from ALPHA Phase III trial of danicopan at ASH

      • NOVN.SW (Novartis) -- presents new results from Phase III APPLY-PNH trial of Fabhalta

      • SAN.FP (Sanofi) -- presents results from IsKia trial of Sarclisa at ASH

      • ROG.SW (Roche Holding) -- presents new data from CD20xCD3 T-cell engaging bispecific antibody program at ASH

      • ROG.SW (Roche Holding) -- reports new data reinforces the benefit of early preventative treatment with Genentech's Hemlibra for babies with severe hemophilia A

      • ROG.SW (Roche Holding) -- Roche presented positive results from the Phase III INAVO120 study evaluating inavolisib in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

      • ROG.SW (Roche Holding) -- Roche's Genentech reports long-term follow-up data from Phase III KATHERINE study of Kadcyla

      • GLPG.NA (Galapagos) -- presents new data from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 at ASH 2023

      • KPTI (Karyopharm Therapeutics) -- presents 24-week follow-up data from phase 1 study of Selinexor 60mg and Ruxolitinib in JAK inhibitor (JAKi)-Navee Myelofibrosis patients

      • FGEN (Fibrogen) -- presents data from Phase 3 MATTERHORN trial of roxadustat in patients with anemia of lower risk transfusion-dependent MDS at ASH

      • MOR.GR (Morphosys) -- Morphosys' Pelabresib improves all four hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 study

      • GETI.B.SS (Getinge) -- FDA identifies CARDIOHELP Emergency Drive as a class I recall

      • PSTX (Poseida Therapeutics) -- presents positive early results from its Phase 1 trial of allogeneic CAR-T P-BCMA-ALLO1 in relapsed-refractory multiple myeloma at ASH

      • ACLX (Arcellx) -- announces continued robust long-term responses from its CART-ddBCMA (anito-cel) Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at ASH

      • IPH.FP (Innate Pharma) -- presents positive results from TELLOMAK Phase 2 study with lacutamab in patients with Szaryy Syndrome at ASH

      • IPH.FP (Innate Pharma) -- Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

      • MOLN.SW (Molecular Partners) -- presents positive initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at ASH

      • VINC (Vincerx Pharma) -- presents preclinical VIP943 and VIP924 posters at ASH

      • COPN.SW (Cosmo Pharmaceuticals) -- Cosmo Intelligent Medical Devices, Medtronic to expand partnership; Medtronic to pay Cosmo $100M (€92.9M) up front

      • ADXN.SW (Addex Therapeutics) -- SEC filing: SC 13D/A (Filed by Growth Equity Opportunities Fund IV, LLC)

      • BGBIO.NO (BerGenBio) -- announces final Bemcentinib phase 2 data in AML and MDS presented at the 2023 ASH meeting

    • Other

      • VOW.GR (Volkswagen) -- in talks with potential partners including Renault to cooperate on development of EV priced below €20,000 - Handelsblatt

      • CBK.GR (Commerzbank) -- discloses ECB determination for SREP P2R capital requirement in 2024

      • FPE3.GR (FUCHS SE) -- announces expansion and prolongation of share buyback

      • BAMI.IM (Banco BPM) -- notes outcome of 2023 ECB SREP

      • UN01.GR (Uniper) -- shareholders approve proposed share capital reduction from current €14.2B to €416.5M at EGM (8-Dec, post-close)

      • Estimated weekend box office revenues in US, Canada $65.4M, +73.5% y/y - Box Office Mojo

      • Euronext announces update on quarterly review results of the ISEQ 20

      • Nasdaq announces semi-annual changes to the OMX Copenhagen 25 Index (

      • Sipef holder Ackermans & van Haaren raises stake to ~40.01% as of 4-Dec - Filing

  • Key rating changes

    • Upgrades

      • CARL.B.DC (Carlsberg) -- to buy from hold at HSBC

      • EOAN.GR (E.ON) -- to buy from neutral at UBS

      • NG.LN (National Grid) -- to buy from neutral at UBS

      • GEN.LN (Genuit Group) -- to buy from add at Peel Hunt

      • ORSTED.DC (Ørsted) -- to equal weight from underweight at Barclays

      • QQ.LN (QinetiQ Group) -- to overweight from neutral at JPMorgan

      • SUBC.NO (Subsea 7) -- to neutral from underweight at JPMorgan

      • RKT.LN (Reckitt) -- to outperform from market perform at Bernstein

      • ULVR.LN (Unilever) -- to market perform from underperform at Bernstein

    • Downgrades

      • RI.FP (Pernod Ricard) -- to reduce from hold at HSBC

      • FORTUM.FH (Fortum) -- to neutral from buy at UBS

      • SSE.LN (SSE) -- to neutral from buy at UBS

      • BEI.GR (Beiersdorf) -- to market perform from outperform at Bernstein

      • ORK.NO (Orkla) -- to underperform from market perform at Bernstein

      • AAL.LN (Anglo American) -- to market perform from outperform at BMO Capital Markets

      • LONN.SW (Lonza) -- to underperform from outperform at RBC Capital Markets

    • Initiations

      • UBS initiates CEZ.CP (sell), PNN.LN (buy), UU.LN (neutral), and VER.AV (sell)

  • Data

    • Nikkei +1.50% to 32791.80

    • Hang Seng (0.95%) to 16178.78

    • Shanghai Composite +0.69% to 2990.02

    • S&P futures (2.8) vs prior close of 4607.5

    • €-$ +0.0009 or +0.08% to 1.0770

    • $-¥ +0.39 or +0.27% to 145.47

    • €-¥ +0.58 or +0.37% to 156.65

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE